STAT

APRIL 3, 2024

The booming class of GLP-1 drugs that includes Ozempic and Wegovy is not only effective for diabetes and obesity, but is also showing early potential to help with conditions involving the brain, like mental health disorders , Alzheimer’s, and even, as new study results suggest — Parkinson’s disease. In a Phase 2 trial, patients with early Parkinson’s disease taking an older GLP-1 diabetes drug called lixisenatide experienced no worsening of motor symptoms over a year,

Diabetes 363

Diabetes Drug Development 363

PharmaVoice

APRIL 3, 2024

AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.

325

325

STAT

APRIL 3, 2024

For around 20 years, Avi Veidman spent his days in the Israeli intelligence community, analyzing satellite images. That was until 2017, when he founded a startup called Nucleai. Now, he’s scouring biopsy samples for cancer cells. Nucleai’s technology is not searching out signs of danger. Instead, the company’s technology maps the proximity of cancer cells, healthy cells, and proteins.

333

333

Med Ed 101

APRIL 3, 2024

The North American Pharmacist Licensure Examination (NAPLEX) is the clinical exam that allows a pharmacy graduate to become a licensed pharmacist. The NAPLEX is designed to evaluate your knowledge of pharmacy practice and is required for pharmacist licensure. It is a 6-hour exam composed of 225 questions, and students are allowed 5 attempts to pass […] The post What Do The 2023 NAPLEX Pass Rates Mean For 2024?

105

105

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Communication

STAT

APRIL 3, 2024

In the next 24 hours, more than 130 people will die from opioid-related drug overdoses. That will happen again tomorrow and the next day. Each year, the U.S. is losing roughly 110,000 people to these deaths of addiction, mostly from illicit opioids like heroin and fentanyl. Under pressure to help combat this public health crisis, the Food and Drug Administration has begun taking steps intended to reduce overdoses and opioid use disorder.

340

340

BioPharma Dive

APRIL 3, 2024

The startup claims to have a more efficient way to develop biologic drugs that treat disease by turning on cellular pathways, rather than blocking them.

114

114

Pharma Times

APRIL 3, 2024

The third most common and serious form of cancer affects over 43,000 people every year in the UK

133

133

STAT

APRIL 3, 2024

LONDON — Moderna may be best known for its Covid-19 vaccine, but since its start, it’s always been set on developing therapies. It’s run into some hurdles as it’s pioneered turning mRNA — the strand of genetic material that’s at the heart of Moderna’s approach — into medicines. But the company’s vision of making cells into their own drug factories is showing signs of progress.

Vaccines 323

Vaccines Drug Development 323

The Pharmacist

APRIL 3, 2024

A pharmacy ear health pilot which had been seen to make 'a huge difference' to patients in South West London will not be recommissioned due to funding constraints, The Pharmacist has learned. The ear care pilot, which was featured by NHS England in a recent national blog, found that delivering the service through community pharmacies […] The post Successful pharmacy ear health pilot will not be recommissioned appeared first on The Pharmacist.

Community Pharmacies 102

Community Pharmacies 102

STAT

APRIL 3, 2024

The Food and Drug Administration approved a new device from Abbott meant to treat tricuspid heart valve disease — an expected decision after an outside advisory panel voted that the device’s benefits outweighed its risks. The device, called the TriClip, addresses a disease called tricuspid regurgitation, in which blood leaks backward through the tricuspid heart valve.

290

290

Advertisement

Managing HR tasks like payroll, compliance, and employee data can overwhelm small businesses. That’s where a Human Capital Management (HCM) solution comes in. Our eBook, Why Every Small Business Needs an HCM Solution: A Comprehensive Guide , shows how an HCM system automates tedious processes, ensuring your business stays compliant and efficient. You’ll learn how to simplify payroll, eliminate costly errors, and empower your employees with self-service tools.

Express Pharma

APRIL 3, 2024

As per Tracxn.com data, 58.5 per cent of funding in Q12024 in early-stage rounds Total funding in the healthtech, lifesciences and healthcare space was $180 million in Q1 2024, a slight drop of 4 per cent from Q1 2023, but a sharp decline of 70 per cent when compared with Q4 2023. This sector raised $187 million and $607 million in Q1 2023 and Q4 2023 respectively.

101

101

STAT

APRIL 3, 2024

Senators Ed Markey and Elizabeth Warren on Wednesday slammed Steward Health Care and its embattled leader Ralph de la Torre, blaming corporate greed and mismanagement for the  financial woes that have called into question the future of the for-profit company’s nine Massachusetts hospitals. “Steward Health Care, led by Dr. Ralph de la Torre, Cerberus [Capital Management], and Medical Properties Trust, and greedy corporate executives like them are failing in their responsibility

Hospitals 246

Hospitals 246

Outsourcing Pharma

APRIL 3, 2024

Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.

Drug Development 96

Drug Development 96

STAT

APRIL 3, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Today we talk about how biopharma plans to harness AI for clinical trial design, why two experts think Medicare ought to cover the costly GLP-1 drugs, and what news from Roivant means for its business strategy.

Drug Pricing 244

Drug Pricing Drug Development 244

Speaker: Joe Sharpe and James Carlson

Payroll optimization can be one of the most time-consuming and complex factors of small business management. Yet, organizations that crack the code on streamlining employee compensation often discover innovative avenues for growth. With the right strategies in place, outsourcing and streamlining payroll processes can result in substantial time and resource savings.

Express Pharma

APRIL 3, 2024

AI and ML-assisted platform reduced cycle time from chemical design to synthesis and testing by 35 per cent Aurigene Pharmaceutical Services (Aurigene), a contract research, development, and manufacturing services organization (CRDMO) and a Dr. Reddy’s Laboratories company, introduced Aurigene.AI, an AI and ML-assisted platform for accelerating drug discovery projects from hit identification to candidate nomination.

Compounding 90

Compounding 90

STAT

APRIL 3, 2024

Investors have funneled $275 million into a revamped biotech developing new psoriasis and psoriatic arthritis treatments that could be given just once or twice a year. The new Oruka Therapeutics launched Wednesday through a reverse merger with ARCA biopharma, a Colorado biotech that has undergone several iterations over the last 30 years. With the merger, ARCA’s plans are being cast aside in favor of Oruka’s antibody medicines, which came from spinout-generator Paragon Therapeutics

212

212

Express Pharma

APRIL 3, 2024

Dr. Pathak will oversee all aspects of quality and regulatory compliance for Lupin’s global operations Lupin announced the appointment of Dr. Ranjana Pathak as Chief Quality Officer, succeeding Johnny Mikell who will be retiring from the services of the company. With over three decades of industry experience, Dr. Pathak brings a wealth of expertise and leadership and will oversee all aspects of quality and regulatory compliance for Lupin’s global operations.

Dosage 90

Dosage 90

Outsourcing Pharma

APRIL 3, 2024

Dr Laura Trotta joined CluePoints in 2015 and moved into her current role as vice president of research in January 2022, where she leads a team of research scientists responsible for developing new statistical and machine learning algorithms to assess the quality of clinical trial data.

89

89

Advertisement

Running a healthcare facility requires precision and care, not just for patients but also for your staff. Our guide, "A Buyer’s Guide to Payroll & HCM Services," helps healthcare providers choose the best provider. Efficient payroll management ensures timely, accurate payments, critical for maintaining staff morale and trust. Compliance support helps navigate complex healthcare regulations and avoid costly fines.

pharmaphorum

APRIL 3, 2024

This critical year for drug discount management includes changes to the 340B programme, implications for Medicare, and updates on the Inflation Reduction Act.

97

97

The Pharmacist

APRIL 3, 2024

The theme of World Pharmacists Day 2024 on 25 September will be ‘Pharmacists: meeting global health needs’, the International Pharmaceutical Federation (FIP) has announced. Part of FIP’s efforts to showcase the crucial role of pharmacists as integral members of healthcare systems, the campaign will celebrate the profession and remind decision-makers and the public of pharmacists’ […] The post FIP announces theme for World Pharmacists Day 2024 appeared first on The Pharmacist.

84

84

Express Pharma

APRIL 3, 2024

Slump sale to be effective on or before October 1, 2024 The Mankind Pharma’s Board of Directors approved the slump sale of the Over the Counter (OTC) business of the company to a wholly owned subsidiary company proposed to be incorporated with the name of Mankind Consumer Products Private Limited or any other name as approved by the Ministry of Corporate Affairs.

86

86

Pharma Times

APRIL 3, 2024

The progressive neurodegenerative disease is estimated to affect 24 million people globally

108

108

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 3, 2024

Basilea Pharmaceutica gets US approval for its ceftobiprole antibiotic, around 15 years after the drug was first turned down by the FDA.

97

97

Express Pharma

APRIL 3, 2024

Pushes the accelerator for three-phased Genome Valley: Rx Propellant Welcoming the announcement of a much-awaited elevated corridor in Hyderabad last month, Rx Propellant, a leading life sciences infrastructure platform and a major developer in the city’s Genome Valley, has said that this will accelerate holistic development of the suburban Hyderabad that in turn will benefit the entrepreneurial ecosystem, including life sciences companies.

Hospitals 77

Hospitals 77

BioPharma Dive

APRIL 3, 2024

The buyout continues a surge in M&A for developers of antibody-drug conjugates and gives Genmab a potential competitor to a medicine AbbVie recently purchased in a multibillion-dollar acquisition.

70

70

World Pharma News

APRIL 3, 2024

A novel treatment for leukemias and lymphomas that arise from immune system T cells, developed by investigators at the Johns Hopkins Kimmel Cancer Center and its Ludwig Center and Lustgarten Laboratory, was found to be effective at killing these cancers in mice bearing human T-cell tumors. The therapy, an antibody-drug conjugate (ADC), combines an antibody that targets a protein called TRBC1 expressed on the surface of T-cell cancers with an anti-cancer drug, called SG3249.

Immunization 81

Immunization Immunity 81

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

Pharmafile

APRIL 3, 2024

Eko Health has announced that the US Food and Drug Administration (FDA) has approved its Low Ejection Fraction (Low EF) detection artificial intelligence (AI). This marks a significant step forward in detection of Low EF, with the tool detecting this within 15 seconds during a routine physical examination when using an Eko stethoscope. The Low […] The post FDA approves Eko Health’s AI for heart failure detection appeared first on Pharmafile.

64

64

Welltopia Pharmacy

APRIL 3, 2024

Discover the link between Vitamin D and Cardiovascular Health. Learn how D3XTRA supports cardiovascular wellness and offers vital benefits.

80

80

Putting Patients First Blog

APRIL 3, 2024

GUEST POST: Now is the Time to Act for Patients April 3, 2024 By: Robert Anderson, VP of Corporate Affairs, Boehringer Ingelheim USA Corporation; President, Boehringer Cares Foundation At Boehringer Ingelheim, we believe in taking action. As a patient-first company that thrives on developing innovative therapies, we firmly believe that everyone deserves access to affordable medicines and treatments and that’s why we decided we could not wait and are introducing a solution now.

Drug Pricing 59

Drug Pricing 59

Pharmafile

APRIL 3, 2024

EnteroBiotix has announced that it has dosed the first patient in its multi-centre, randomised, double-blind, placebo controlled clinical trial, which is intended to assess EBX-102-02 for the treatment of patients with irritable bowel disease (IBS). The phase 2 TrIuMPH study will enroll 60 patients with IBS and constipation across sites in the UK, with the […] The post EnteroBiotix begins phase 2 trial of IBS treatment appeared first on Pharmafile.

59

59

BioPharma Dive

APRIL 3, 2024

Oruka Therapeutics is the third startup from Paragon to go public since last year, and the second to do so by combining with another biotech.

67

67